CII
RARE icon

Capital International Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital International Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,429
Closed -$1.09M – 308
2022
Q3 		$1.09M Sell
26,429
-8,184
-24% -$421K 0.02% 253
2022
Q2 		$2.06M Sell
34,613
-6,879
-17% -$423K 0.03% 223
2022
Q1 		$3.01M Sell
41,492
-58,206
-58% -$4.05M 0.03% 209
2021
Q4 		$8.38M Sell
99,698
-251,801
-72% -$20.5M 0.08% 172
2021
Q3 		$31.7M Sell
351,499
-47,682
-12% -$4.31M 0.31% 99
2021
Q2 		$38.1M Sell
399,181
-24,776
-6% -$2.58M 0.34% 102
2021
Q1 		$48.3M Sell
423,957
-61,909
-13% -$8.43M 0.45% 78
2020
Q4 		$67.3M Buy
485,866
+5,033
+1% +$597K 0.62% 54
2020
Q3 		$39.5M Buy
480,833
+2,975
+0.6% +$247K 0.44% 81
2020
Q2 		$37.4M Buy
477,858
+27,363
+6% +$1.81M 0.46% 81
2020
Q1 		$20M Buy
450,495
+7,835
+2% +$407K 0.34% 96
2019
Q4 		$18.9M Sell
442,660
-28,405
-6% -$1.17M 0.26% 105
2019
Q3 		$20.2M Buy
471,065
+396,300
+530% +$21.5M 0.3% 103
2019
Q2 		$4.75M Buy
74,765
+26,715
+56% +$1.7M 0.33% 81
2019
Q1 		$3.33M Buy
48,050
+4,109
+9% +$235K 0.4% 58
2018
Q4 		$1.91M Sell
43,941
-900
-2% -$49.2K 0.26% 83
2018
Q3 		$3.42M Buy
44,841
+10,801
+32% +$879K 0.45% 58
2018
Q2 		$2.62M Sell
34,040
-7,100
-17% -$459K 0.4% 57
2018
Q1 		$2.1M Sell
41,140
-2,100
-5% -$106K 0.3% 69
2017
Q4 		$2M Sell
43,240
-2,860
-6% -$140K 0.3% 75
2017
Q3 		$2.46M Sell
46,100
-6,600
-13% -$391K 0.36% 67
2017
Q2 		$3.27M Sell
52,700
-4,300
-8% -$259K 0.47% 54
2017
Q1 		$3.86M Buy
57,000
+9,900
+21% +$754K 0.47% 57
2016
Q4 		$3.31M Buy
47,100
+11,900
+34% +$844K 0.41% 62
2016
Q3 		$2.5M Buy
+35,200
New +$2.25M 0.3% 65

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Capital International Inc's RARE Position: Q4 2022 in Review

Capital International Inc sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 26,429 shares — an estimated $1.09M sold.

Capital International Inc first reported a position in RARE in Q3 2016 and held it in 25 quarters. The position peaked at $67.3M in Q4 2020. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Capital International Inc reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Capital International Inc sold 26,429 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $1.09M.
  • Capital International Inc first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 25 quarters.
  • Capital International Inc's Ultragenyx Pharmaceutical position peaked at $67.3M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Capital International Inc's 13F filing for Q4 2022, filed 14 Feb 2023.